Recent investigations have converged on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and dopaminergic neurotransmission. While GIP activators are increasingly employed for managing type 2 T2DM, their potential consequences on reinforcement circuits, specifically influenced by dopa